These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8069268)
1. Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. Hashimoto H; Umemura K; Araki S; Ishii M; Nagashima S; Uematsu T; Nakashima M Biol Pharm Bull; 1994 Apr; 17(4):548-50. PubMed ID: 8069268 [TBL] [Abstract][Full Text] [Related]
2. Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation. Jackson N; Verma SP; Frais MA; Silke B; Hafizullah M; Reynolds G; Taylor SH Clin Pharmacol Ther; 1985 Jun; 37(6):619-24. PubMed ID: 3891187 [TBL] [Abstract][Full Text] [Related]
3. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Coromilas J; Saltman AE; Waldecker B; Dillon SM; Wit AL Circulation; 1995 Apr; 91(8):2245-63. PubMed ID: 7697855 [TBL] [Abstract][Full Text] [Related]
4. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. van Middendorp LB; Strik M; Houthuizen P; Kuiper M; Maessen JG; Auricchio A; Prinzen FW Europace; 2014 Aug; 16(8):1249-56. PubMed ID: 24481779 [TBL] [Abstract][Full Text] [Related]
5. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. Kondoh K; Hashimoto H; Nishiyama H; Umemura K; Ozaki T; Uematsu T; Nakashima M J Cardiovasc Pharmacol; 1994 Apr; 23(4):674-80. PubMed ID: 7516022 [TBL] [Abstract][Full Text] [Related]
6. [Modification of hemodynamics by intravenous administration of flecainide]. Hoffmeister HM; Hepp A; Seipel L Z Kardiol; 1986 Mar; 75(3):176-81. PubMed ID: 3705689 [TBL] [Abstract][Full Text] [Related]
7. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. Ikeda N; Singh BN; Davis LD; Hauswirth O J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):303-10. PubMed ID: 3968315 [TBL] [Abstract][Full Text] [Related]
8. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
9. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs. Ogawa S; Mitamura H; Katoh H Cardiovasc Drugs Ther; 1993 Aug; 7 Suppl 3():621-6. PubMed ID: 8251432 [TBL] [Abstract][Full Text] [Related]
11. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. Xue YX; Arita J; Aye NN; Hashimoto K Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724 [TBL] [Abstract][Full Text] [Related]
12. Comparative hemodynamic effects of Org 7797, flecainide, and propafenone in anesthetized pigs with developing myocardial infarcts. Winslow E; Mason R J Cardiovasc Pharmacol; 1992 Mar; 19(3):435-41. PubMed ID: 1378126 [TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics. Fujiki A; Tani M; Hayashi H; Mizumaki K; Inoue H; Uemura H; Nakaya H J Cardiovasc Pharmacol; 1997 Apr; 29(4):471-5. PubMed ID: 9156356 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine. Kondo T; Yamaki M; Kubota I; Tachibana H; Tomoike H J Am Coll Cardiol; 1997 Jun; 29(7):1639-44. PubMed ID: 9180130 [TBL] [Abstract][Full Text] [Related]
15. Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. Sakai T; Ogawa S; Hosokawa M; Miyazaki T; Sakurai K; Nakamura Y Cardiovasc Res; 1989 Mar; 23(3):177-83. PubMed ID: 2512008 [TBL] [Abstract][Full Text] [Related]
16. The antiarrhythmic and hemodynamic actions of alpha, alpha-dimethyl-4-(alpha, alpha, beta, beta-tetrafluorophenethyl) benzylamine (MK-251). Torchiana ML; Stone CA; Wenger HC; Evans R; Lagerquist B; O'Malley T J Pharmacol Exp Ther; 1975 Aug; 194(2):415-26. PubMed ID: 1151767 [TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic effects of flecainide against canine ventricular arrhythmias induced by two-stage coronary ligation and halothane-epinephrine. Dobmeyer D; Muir WW; Schaal SF J Cardiovasc Pharmacol; 1985; 7(2):238-44. PubMed ID: 2581074 [TBL] [Abstract][Full Text] [Related]
18. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction. Hashimoto H; Satoh N; Nakashima M J Cardiovasc Pharmacol; 1992 Mar; 19(3):417-24. PubMed ID: 1378123 [TBL] [Abstract][Full Text] [Related]
19. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638 [TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic interaction between class I antiarrhythmic drugs and volatile anesthetics in depressant effects on ventricular activation in a canine myocardial infarction model. Hashimoto H; Imamura S; Ikeda K; Nakashima M Jpn J Pharmacol; 1994 Apr; 64(4):235-41. PubMed ID: 8057524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]